#GLANDPHARMA Thread covering some fundamentals of its business (Not in any sequence).........
It has no listed peer because:
1. It has a B2B led business (95% of topline)
2. They produce complex injectables
It has no listed peer because:
1. It has a B2B led business (95% of topline)
2. They produce complex injectables
Manufacturing facilities are approved by following:
FDA –USA•Health –Canada•UK –MHRA •WHO –Geneva• TGA –Australia•BGV –Hamburg (Germany)•MCC –South Africa•SUKL –Czech Republic•ANVISA –Brazil•INVIMA –Colombia•NAFDAC –Nigeria•NDA –Uganda•PPB –Kenya • FMHCA –Ethiopia
FDA –USA•Health –Canada•UK –MHRA •WHO –Geneva• TGA –Australia•BGV –Hamburg (Germany)•MCC –South Africa•SUKL –Czech Republic•ANVISA –Brazil•INVIMA –Colombia•NAFDAC –Nigeria•NDA –Uganda•PPB –Kenya • FMHCA –Ethiopia
Total 51 API approved for sale in USA. Not even one more than this list. 
-Total 22 more API are currently under development
-Very high attrition rate.
-Company manpower is skewed towards QA/QC so high attrition rate is not good.
-They never got USFDA 483 for any of their facility
-Onco facility expansion is going on right now.
-Very high attrition rate.
-Company manpower is skewed towards QA/QC so high attrition rate is not good.
-They never got USFDA 483 for any of their facility
-Onco facility expansion is going on right now.
-India business generates 4%, for which they have a workforce of 200 employee. This is extremely poor performance by any angle. Either India business is higher or they not over reporting number of employees in India sales team.
-Have filled 265 ANDA in USA with their partners. 100 out of them belongs to them.
- If you want to see product list, see page 126 to 128 of DRHP
-To know about manufacturing facilities, see page 130 and 131 of DHRP
-Dundigal plant is their manufacturing mothership
- If you want to see product list, see page 126 to 128 of DRHP
-To know about manufacturing facilities, see page 130 and 131 of DHRP
-Dundigal plant is their manufacturing mothership
BIGGEST RISK IN THEIR MANUFACTURING FACILITIES
-Manufacturing is poorly skewed towards Dundigal.There is no word frm mgmt to derisk the products from that plant. One 483 on that plant can damage whole equation of business
-The products capacities across plants are not uniform
-Manufacturing is poorly skewed towards Dundigal.There is no word frm mgmt to derisk the products from that plant. One 483 on that plant can damage whole equation of business
-The products capacities across plants are not uniform
-Given their spending on R&D in 2018/19/20 as 61cr, 96Cr, 92Cr the increase in top-line is very good.
-They spent extremely less on CSR Activities in 2018/2019. In 2020 they increased CSR due to IPO. A Symbol of greediness.
-They spent extremely less on CSR Activities in 2018/2019. In 2020 they increased CSR due to IPO. A Symbol of greediness.
-The Organization chart dont have a senior position to anyone from QA/QC. This is not per Industry Standard. See page 164/165 of DRHP. By the way who liaison from QA side in USFDA Audits? Very Strange.....
Whole umbrella of contract services covers all these(They do almost everything as a contract organization):
• • •
Missing some Tweet in this thread? You can try to
force a refresh
